Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson
Paul
P
Anderson
Kenneth
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003907:Dexamethasone / Q000008:administration & dosage* / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D006801:Humans; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin